Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial)

For gastric cancer patients, surgical resection with en-bloc lymphadenectomy is the cornerstone of curative treatment. Open gastrectomy has long been the preferred surgical approach worldwide. However, this procedure is associated with considerable morbidity. Several meta-analyses have shown an adva...

Full description

Saved in:
Bibliographic Details
Published inBMC cancer Vol. 15; no. 1; p. 556
Main Authors Haverkamp, Leonie, Brenkman, Hylke J F, Seesing, Maarten F J, Gisbertz, Suzanne S, van Berge Henegouwen, Mark I, Luyer, Misha D P, Nieuwenhuijzen, Grard A P, Wijnhoven, Bas P L, van Lanschot, Jan J B, de Steur, Wobbe O, Hartgrink, Henk H, Stoot, Jan H M B, Hulsewé, Karel W E, Spillenaar Bilgen, Ernst J, Rütter, Jeroen E, Kouwenhoven, Ewout A, van Det, Marc J, van der Peet, Donald L, Daams, Freek, Draaisma, Werner A, Broeders, Ivo A M J, van Stel, Henk F, Lacle, Miangela M, Ruurda, Jelle P, van Hillegersberg, Richard
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 29.07.2015
BioMed Central
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:For gastric cancer patients, surgical resection with en-bloc lymphadenectomy is the cornerstone of curative treatment. Open gastrectomy has long been the preferred surgical approach worldwide. However, this procedure is associated with considerable morbidity. Several meta-analyses have shown an advantage in short-term outcomes of laparoscopic gastrectomy compared to open procedures, with similar oncologic outcomes. However, it remains unclear whether the results of these Asian studies can be extrapolated to the Western population. In this trial from the Netherlands, patients with resectable gastric cancer will be randomized to laparoscopic or open gastrectomy. The study is a non-blinded, multicenter, prospectively randomized controlled superiority trial. Patients (≥18 years) with histologically proven, surgically resectable (cT1-4a, N0-3b, M0) gastric adenocarcinoma and European Clinical Oncology Group performance status 0, 1 or 2 are eligible to participate in the study after obtaining informed consent. Patients (n = 210) will be included in one of the ten participating Dutch centers and are randomized to either laparoscopic or open gastrectomy. The primary outcome is postoperative hospital stay (days). Secondary outcome parameters include postoperative morbidity and mortality, oncologic outcomes, readmissions, quality of life and cost-effectiveness. In this randomized controlled trial laparoscopic and open gastrectomy are compared in patients with resectable gastric cancer. It is expected that laparoscopic gastrectomy will result in a faster recovery of the patient and a shorter hospital stay. Secondly, it is expected that laparoscopic gastrectomy will be associated with a lower postoperative morbidity, less readmissions, higher cost-effectiveness, better postoperative quality of life, but with similar mortality and oncologic outcomes, compared to open gastrectomy. The study started on 1 December 2014. Inclusion and follow-up will take 3 and 5 years respectively. Short-term results will be analyzed and published after discharge of the last randomized patient. NCT02248519.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-015-1551-z